Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa

US Patent 12037387 · Granted Jul 16, 2024

Estimated economic value: $1,820,080,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CD11D antibodies and uses thereof2024
CD200R agonist antibodies and uses thereof2022
Pan-ELR+ CXC chemokine antibodies2020
Pan-ELR+ CXC chemokine antibodies2020
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2018
Anti-CD20− / anti-BAFF bispecific antibodies2018
Anti-CD20− / anti-BAFF bispecific antibodies2018
Pan-ELR+ CXC chemokine antibodies2017
Pan-ELR+ CXC chemokine antibodies2017
Nucleic acids encoding antibodies that bind IL-232017
Anti-TNF-anti-IL-17 bispecific antibodies2016